Wegovy vs Zepbound: Which Should You Choose?
Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are the two FDA-approved once-weekly injections for chronic weight management. They differ in mechanism (Wegovy is a GLP-1 receptor agonist; Zepbound is a dual GIP/GLP-1 agonist), in average weight-loss magnitude in pivotal trials, and in real-world cost.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 15 mg) are the two FDA-approved injectable GLP-1 medications for chronic weight management, and they represent the current gold standard in pharmacological obesity treatment. The STEP 1 trial (NEJM 2021) showed 14.9% mean weight loss with Wegovy; the SURMOUNT-1 trial (NEJM 2022) showed 20.9% with Zepbound. No direct head-to-head trial has been published.
Zepbound's efficacy advantage is real and clinically meaningful — approximately 6 percentage points more mean weight loss in separate Phase 3 trials. Wegovy has the cardiovascular outcomes data: the SELECT trial (NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease. Zepbound's cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing. For most patients without established cardiovascular disease, Zepbound's efficacy advantage makes it the stronger choice if both are accessible and covered.
SkinnyRx
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
FuturHealth
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
Other GLP-1 Programs to Compare
These reviewed GLP-1 programs have category-matched supplied destinations. They are not presented as a guarantee of Wegovy or Zepbound availability; confirm the medication, insurance, dose, pharmacy, and current terms directly before enrolling.
WellMedr
Compounded GLP-1 care with semaglutide shown at $49/mo or tirzepatide at $89/mo with 12-month prepayment; $99/$129 month to month. Verified affiliate coverage is weight loss only.
Side-by-Side Comparison
| Attribute | SkinnyRx | FuturHealth |
|---|---|---|
| Program Fee | Included in monthly plan | Included in monthly plan |
| Medication From | From $99 – $199/mo | From $198 – $395/mo |
| Editor Score | 4.3 / 5 | 4.0 / 5 |
| Primary Category | GLP-1 Weight Loss | GLP-1 Weight Loss |
| FDA Brand-Name Access | Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo | Wegovy, Zepbound, Ozempic, Mounjaro |
| Compounded Options | 4 compounds | 1 compounds |
| Adjacent Categories | GLP-1 Weight Loss | GLP-1 Weight Loss |
What the Studies Actually Show
Percentages below are means from the pivotal Phase 3 trials of each medication. The first direct head-to-head comparison was published in SURMOUNT-5 (NEJM 2025); cross-trial comparisons should still be read as directional. Individual results vary; trial populations differed slightly in baseline BMI and comorbidities.
| Endpoint | SkinnyRx | FuturHealth |
|---|---|---|
| Mean weight loss vs placebo (pivotal trial)1,2 | −14.9% at 68 weeks STEP 1 enrolled adults with BMI ≥30 (or ≥27 with a weight-related comorbidity). SURMOUNT-1 used the same eligibility criteria. Trial-design differences mean these figures cannot be directly compared. | −20.9% at 72 weeks (15 mg dose) |
| Placebo arm weight loss1,2 | −2.4% | −3.1% |
| Proportion losing ≥15% of body weight1,2 | 50.5% of participants | 78.0% (15 mg dose) |
| Most common GI side effects (≥10% incidence)3,4 | Nausea, diarrhea, vomiting, constipation | Nausea, diarrhea, vomiting, constipation |
| Cardiovascular outcomes evidence5 | SELECT trial: 20% MACE risk reduction in adults with established CV disease and overweight/obesity | SURMOUNT-MMO trial ongoing |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approval (chronic weight management)3,4 | June 2021 | November 2023 |
Who Should Choose Wegovy vs Zepbound
Choose Wegovy if…
- You want the drug with a proven cardiovascular benefit (the SELECT trial) or have established heart disease.
- You'd like a pill option on the same molecule later (the Wegovy pill runs $149 to $299 a month).
- Cost matters: the Wegovy pen is $349 a month at every standard dose versus $449 for Zepbound at maintenance.
Choose Zepbound if…
- Maximum average weight loss is the priority: tirzepatide produced larger mean losses in its pivotal trial.
- You have obstructive sleep apnea; Zepbound is approved for it, which can open insurance or Medicare coverage.
- You can refill on schedule: the $449 maintenance price requires a refill within 45 days.
Monthly Cost Compared
| Wegovy pen (semaglutide) | Zepbound (tirzepatide) | |
|---|---|---|
| Month 1 | $199 (0.25 mg, new-patient offer) | $299 (2.5 mg) |
| Month 2 | $199 (0.5 mg, new-patient offer) | $399 (5 mg) |
| Maintenance | $349 (1.7 or 2.4 mg) | $449 (7.5 to 15 mg, refilled within 45 days); $699 if late at 10 to 15 mg |
| Approximate first year | $3,888 | $5,188 |
| Oral alternative | Wegovy pill $149 to $299 | Foundayo (orforglipron, a different drug) $149 to $299 |
Self-pay prices from NovoCare and LillyDirect, checked October 21, 2026, assuming one month at each dose step. With commercial insurance that covers the drug, manufacturer savings programs can bring the cost to as little as $25 a month. A prescriber decides the dose schedule.
The Verdict
Tirzepatide (Zepbound) produced greater mean weight loss in its pivotal SURMOUNT-1 trial than semaglutide did in STEP 1, though the trials are not directly comparable. Semaglutide (Wegovy) has been on the market longer and has a deeper real-world safety dataset, including the SELECT cardiovascular outcomes trial. Choose based on insurance coverage, GI tolerance, and clinician judgment.
Frequently Asked Questions
Is Wegovy or Zepbound more effective for weight loss?
In their pivotal trials, Zepbound (tirzepatide) produced larger mean weight loss than Wegovy (semaglutide). −20.9% at 72 weeks at the 15 mg dose vs −14.9% at 68 weeks for Wegovy. The two drugs were never compared head-to-head at full dose, so the difference is directional, not definitive. For most patients, Zepbound's dual GIP/GLP-1 mechanism translates to greater absolute weight loss; Wegovy has the deeper real-world dataset and the only FDA-approved cardiovascular outcomes label.
Which one is cheaper?
Cash-pay pricing is similar: NovoCare offers Wegovy at $499/month for self-pay patients meeting eligibility; LillyDirect offers Zepbound vials at $349–$499/month depending on dose and pen vs vial. With insurance, copays vary widely and depend on whether your plan covers anti-obesity medications. Compounded versions (where available) typically run $250–$400/month. The cheapest path is usually whichever drug your insurance actually covers.
Does Wegovy have any advantage over Zepbound?
Yes, Wegovy has FDA approval for cardiovascular risk reduction in adults with established cardiovascular disease and obesity, based on the SELECT trial showing a 20% reduction in major adverse cardiovascular events. Zepbound does not yet have a parallel CV outcomes label (the SURMOUNT-MMO trial is ongoing). For patients with prior heart attack, stroke, or established atherosclerotic disease, Wegovy is the better-evidenced choice.
Are the side effects different?
The side-effect profiles are similar, both cause nausea, diarrhea, vomiting, and constipation as the most common GI effects, especially during dose escalation. Zepbound trials showed slightly higher rates of mild-to-moderate GI symptoms than Wegovy at peak dose, but tolerability differences are small and individual variation is large. Both carry boxed warnings for thyroid C-cell tumors based on rodent studies; neither has been linked to thyroid cancer in humans.
Can I switch from Wegovy to Zepbound or vice versa?
Yes, switching is common, often driven by insurance changes or weight-loss plateau. Clinicians typically restart at a lower titration step rather than matching the previous dose 1:1, since cross-tolerance between the two drugs is incomplete. Expect 1–2 weeks of GI re-adjustment after switching. There is no clinical rationale for taking both simultaneously.
Which one should I ask my telehealth provider for?
If maximum weight loss is the goal and you have no cardiovascular history, Zepbound is the stronger evidence-based choice. If you have established cardiovascular disease, Wegovy's SELECT trial label makes it the better fit. If your insurance only covers one of the two, that decides for you. Most major telehealth GLP-1 platforms (Eden, Ro, TrimRx, Hims, Found) prescribe both.
- STEP 1 Trial. NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SURMOUNT-1 Trial. NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SELECT Trial. NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.